Patterns and safety of glucocorticosteroid use following CD19 CAR‐T therapy for large B‐cell lymphoma
Open Access
- 27 November 2025
- journal article
- Published by Wiley in HemaSphere
- Vol. 9 (11) , e70248
Abstract
Corticosteroids are commonly used to manage cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) following chimeric antigen receptor (CAR) T‐cell therapy, and yet, their dose‐specific impact on outcomes remains uncertain. We retrospectively evaluated 276 adults with large B‐cell lymphoma (LBCL) treated with CD19‐directed CAR‐T therapy (axi‐cel, tisa‐cel, or liso‐cel) between 2016 and 2023 at a single institution. Cumulative corticosteroid dose was defined as the total dose administered within 21 days of infusion. Corticosteroids were administered to 105 patients (38%), initiated at a median of 5 days post‐infusion (interquartile range [IQR] 3–7) for CRS (38%), ICANS (15%), or both (47%). Use was more frequent with axi‐cel (P < 0.001), although the cumulative dose and duration were similar across products. To assess the impact of corticosteroid exposure, we carried out a 21‐day landmark analysis. Corticosteroid exposure, modeled as a time‐dependent covariate, was not significantly associated with infection risk, non‐relapse mortality, or inferior overall survival (OS) or progression‐free survival (PFS). However, in a landmark analysis, patients receiving above‐median cumulative corticosteroid doses had a significantly higher risk of infection compared to those receiving below‐median corticosteroid doses or no corticosteroids (P = 0.042). In a landmark multivariable analysis, corticosteroid cumulative dose was associated with increased late hematologic toxicity (adjusted hazard ratio [HR] 1.02, 95% CI 1.02–1.03). Finally, in a sensitivity analysis excluding patients with Grade ≥4 CRS/ICANS, corticosteroid cumulative dose remained unassociated with OS or relapse, but was linked to shorter PFS (adjusted HR 1.04, 95% CI 1.01–1.06). These findings support the safe yet judicious use of corticosteroids to manage CAR‐T toxicities in LBCL.Keywords
This publication has 40 references indexed in Scilit:
- Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T ConsortiumJournal of Clinical Oncology, 2020
- Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemiaBlood Cancer Journal, 2020
- Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)Haematologica, 2019
- The REDCap consortium: Building an international community of software platform partnersJournal of Biomedical Informatics, 2019
- ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector CellsTransplantation and Cellular Therapy, 2019
- Immune regulation by glucocorticoidsNature Reviews Immunology, 2017
- Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano ClassificationJournal of Clinical Oncology, 2014
- Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic LeukemiaScience Translational Medicine, 2014
- Targeting interleukin-6 in inflammatory autoimmune diseases and cancersPharmacology & Therapeutics, 2014
- Glucocorticoids in T cell apoptosis and functionCellular and Molecular Life Sciences, 2005